Optimizing Care of the Inpatient with Hyperglycemia and Diabetes: Case Studies in Action
|
|
- Marilyn Richardson
- 5 years ago
- Views:
Transcription
1 Optimizing Care of the Inpatient with Hyperglycemia and Diabetes: Case Studies in Action Learning Objectives Identify patient situations where specific attention to glycemic control is warranted Determine whether patients in specific situations are at greater or lesser risk of hyperglycemia and/or hypoglycemia Describe specific situations where glucose control is particularly challenging 2 1
2 Case Studies Available Insulin needs in patients on high dose steroids Insulin needs and nutrition (enteral, total parenteral) Insulin needs in patients undergoing surgery Transition to outpatient status Use of insulin pumps in the hospital Inpatient Hyperglycemia and Poor Outcomes in Numerous Settings Study Pidala et al, 2011 Patient Population Steroid use in transplant patients Significant Hyperglycemia-Related Outcomes Mortality risk Sarkisian et al, 2009 Total parenteral nutrition Mortality risk, ARF Pasquel et al, 2010 Total parenteral nutrition Mortality risk, pneumonia risk Frisch et al, 2009 Noncardiac surgery Mortality risk, surgery-specific risk Pidala J et al. Biol Blood Marrow Transplant. 2011;17: ; Sarkisian S et al. Can J Gastroenterol. 2010;24: Pasquel FJ, et al. Diabetes Care. 2010;33: ; Frisch A, et al. Diabetes. 2009;58(suppl 1):101-OR. 4 2
3 Current Recommendations for Hospitalized Patients All critically ill patients in intensive care unit settings BG level mg/dl Intravenous insulin preferred Non critically ill patients Random: <180 mg/dl Pre-meal: <140 mg/dl Scheduled SC insulin preferred Sliding-scale insulin discouraged Hypoglycemia Reassess the regimen if BG level is <100 mg/dl Modify the regimen if BG level is <70 mg/dl AACE and ADA Consensus Statement on Inpatient Statement on Inpatient Glycemic Control. Endocr Pract. 2009;15: Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab,.2012;97: Case Study: Steroids 78-year-old woman is hospitalized for worsening dyspnea and cough She has had chronic obstructive pulmonary disease (COPD) since age 55 No prior history of diabetes 6 3
4 Case Study: Steroids Medications Fluticasone propionate 2 puffs twice a day Albuterol inhaler, 2 puffs as needed Amlodipine 5 mg 1 daily, Lisinopril 10mg 1 daily (HTN) Simvastatin 20 mg 1 daily (Cholesterol) 7 Case Study: Steroids Examination Mild respiratory distress Afebrile O2 sat: 91% on room air Diffuse pulmonary wheezes Normal heart sounds No edema 8 4
5 Case Study: Steroids Laboratory Values WBC: 12.5 Lytes normal; BUN: 12/ SCr: 0.9 ABG: ph 7.45, PCO2 32, P02 64 Random glucose: 150 mg/dl A1C : 6.2% 9 Case Study: Steroids Patient admitted and started on Solumedrol 40 mg IV q 6 hrs BG on day 2 climbs to 210 mg/dl 10 5
6 What is your assessment of this patient s glycemic status? 1. New onset diabetes 2. Steroid-induced hyperglycemia 3. Stress-induced hyperglycemia (disease-related) 11 Frequency of Hyperglycemia in Patients Receiving High-dose Corticosteroids All Pa ents Percent 70 No Documented History of Diabetes History of Diabetes > 2 BG > 200 mg/dl Episodes > 1 BG > 200 mg/dl High-dose defined as a dose equivalent of at least 40 mg per day of prednisone. Donihi AC, et al. Endocr Pract. 2006;12(4):
7 Hyperglycemia and Steroids Common complication of glucocorticoid therapy prevalence 20-50% among patients without a prior DM history Results from Increases in hepatic glucose production Impairment of glucose uptake in peripheral tissues, All of this contributes to increases in postprandial glucose Predictors: Total glucocorticoid dose Duration of glucocorticoid therapy Increasing age Umpierrrez G et al. J Clin Endocrinol Metab Jan;97(1): Clore JN, et al. Endocr Pract. 2009;15(5): How would you treat this patient? 1. Sliding scale insulin 2. Standard basal bolus insulin therapy 3. Basal bolus therapy with emphasis on postprandial glucose levels 4. Intravenous insulin therapy 5. No glucose lowering therapy required 14 7
8 General Recommendations: Hyperglycemia Associated with Steroids Discontinue OADs Initiate sc basal bolus insulin therapy is recommended Starting insulin dose and timing of insulin administration individualized depending on severity of hyperglycemia and duration and dosage of steroid therapy. Suggested starting dosage of 0.3 to 0.5 U /kg d For patients receiving high-dose glucocorticoids and in those with severe hyperglycemia that is difficult to control, the use of continuous insulin infusion may be appropriate Umpierrrez G et al. J Clin Endocrinol Metab Jan;97(1): Moghissi ES, et al. Endocr Pract. 2009;15: Basal Bolus Therapy with Emphasis on Nutritional Insulin Medium-dose glucocorticoids (40 60 mg/d) tend to cause minimal increase in FPG and marked elevation in PPG Scheduled Basal Nutritional* Insulin drip NPH Long-acting insulin analog (glargine, detemir) Emphasis on regular or rapid-acting insulin analog Supplemental/ Correction* Regular or rapidacting insulin analog q4 6h Analog Mixes Clement S, et al. Diabetes Care. 2004;27: Moghissi ES, et al. Endocr Pract. 2009;15: * Rapid analog preferred 16 8
9 Hyperglycemia and Glucocorticoid Therapy: Summary Institute glucose monitoring for at least 48 hours in all patients Prescribe insulin therapy as needed according to results of bedside BG monitoring During initiation and taper of steroid therapy, proactive adjustment of insulin therapy can help avoid uncontrolled hyperglycemia and hypoglycemia Umpierrrez G et al. J Clin Endocrinol Metab Jan;97(1): Moghissi ES, et al. Endocr Pract. 2009;15: Insulin needs and nutrition (enteral, total parenteral) 9
10 Case Study: Nutrition 55-year old obese male is admitted hemorrhagic pancreatitis, no prior history of diabetes On admission, his BG 200 mg/dl A1C 7.5% (previously unrecognized DM) Patient is not eating, and it is anticipated that he will not be able to eat for one week Total parenteral nutrition is started 19 Hyperglycemia During TPN: Marker of Poor Outcomes & Mortality in the Hospital Admission p = p = p = p = < > < > < > > Blood Glucose (mg/dl) Pasquel et al. Diabetes Care. 2010;33:
11 TPN, Glucose and Patient Mortality Study Hyperglycemia definition (mg/dl) Mortality Odds Ratio Cheung (2005) > Lin (2007) > Sarkisian (2009) Pasquel (2010) > Olveira (2012) > Case Study: Total Parenteral Nutrition What is the insulin treatment would you recommend for a DM patient on TPN? 1. IV insulin, separate from TPN 2. Insulin added to TPN 3. Basal bolus insulin 22 11
12 General Recommendations: Hyperglycemia Associated with Parenteral Nutrition (PN) For patients receiving PN, regular insulin administered as part of the PN formulation can be both safe and effective Subcutaneous correction-dose insulin is often used, in addition to insulin that is mixed with the nutrition When starting PN, the initial use of a separate insulin infusion can help in estimating the total daily dose of insulin that will be required. Separate IV insulin infusions may be needed to treat marked hyperglycemia during PN Umpierrrez G et al. J Clin Endocrinol Metab Jan;97(1): Moghissi ES, et al. Endocr Pract. 2009;15: Case Study: Insulin needs and nutrition 70 year old woman admitted with a stroke She has a prior history of T2DM, controlled on oral agents BG on admission 150 mg/dl, A1C 7% She is currently unable to swallow Continuous enteral nutrition is started on hospital day
13 Case Study: Insulin needs and nutrition What is insulin treatment would you recommend for a DM patient on enteral tube feedings? (BG 150 to 300 mg/dl) 1. Sliding scale only with rapid-acting insulin? 2. IV insulin variable rate infusion? 3. NPH or premixed analog 70/30 every 8 hours? 4. Basal insulin every 12 hours? 5. Regular insulin every 6 hours? 25 Complications of Enteral Nutrition A prospective and observational study carried out in 64 patients average age (mean age 76.2 y) receiving EN on an Internal Medicine Inpatient Unit Percent of patients Most frequent complications: Should blood glucose levels be checked in patients receiving enteral nutrition? Pancorbo Hidalgo PL. J Clin Nsa. 2001;10:
14 Glycemic Management of the Patient Receiving Enteral Nutrition Continuous enteral nutrition (EN) Basal: 40-50% of TDD as long or intermediate acting insulin given once twice a day Short acting 50-60% of TDD given q6h Cycled enteral nutrition Intermediate acting insulin given together with a rapid or short acting insulin with start of TF Rapid or short acting insulin administered q4 to 6 hours for duration of EN administration Correctional insulin given for BG above goal range Bolus enteral nutrition Rapid acting or short acting insulin given prior to each bolus Umpierrez et al, Endocrine Society Non-ICU Guideline. J Clin Endocrinol Metab Jan;97(1): Blood Glucose Monitoring In previously normoglycemic patients receiving therapies associated with hyperglycemia, such as corticosteroids, enteral nutrition (EN ), & parenteral nutrition (PN) Bedside point of care (POC) testing is recommended for at least 24 to 48 h after starting these therapies Those with BG measures > 140 mg/dl require ongoing POC testing with appropriate therapeutic intervention Frequent glucose monitoring is indicated in patients treated with medication change that could alter glycemic control, e.g. corticosteroid use or abrupt discontinuation of EN or PN Are patients receiving high-dose steroid therapy having BG levels checked in your institution? Umpierrrez G et al. J Clin Endocrinol Metab Jan;97(1):
15 Insulin needs in patients undergoing surgery Case Study: Surgery 60 year old woman with T2DM treated with insulin is admitted for hip fracture Her outpatient insulin regimen is as follows Premixed analog 70/30, 30 units twice a day Admission glucose = 180 mg/dl 30 15
16 How would you treat this patient? 1. Sliding scale insulin 2. Standard basal bolus insulin therapy 3. Basal bolus therapy with emphasis on postprandial glucose levels 4. Intravenous insulin therapy 5. No glucose lowering therapy required 31 Physiologic Components of Insulin Therapy Basal insulin: detemir (Levemir ), glargine (Lantus ), NPH (Humulin N, Novolin N) The amount of insulin necessary to regulate glucose levels between meals and overnight Nutritional insulin: aspart (NovoLog ), glulisine (Apidra ), lispro (HumaLog ), regular (Humulin R, Novolin R) The amount of insulin required to cover meals, IV dextrose, enteral nutrition, TPN or other nutritional supplements Correctional insulin: (Supplemental insulin) Refers to supplemental doses of rapid or short acting insulin given to correct elevations in blood glucose that occur despite use of basal and nutritional insulin Usually administered before meals together with prandial insulin IV, intravenous; TPN, total parenteral nutrition 32 16
17 Basal-Bolus Superior to Sliding Scale Insulin Treatment for Inpatient Hyperglycemia Mean BG (mg/dl) * 200 * * Basal-bolus SSI Admit Days of Therapy No differences in the rate of hypoglycemia or hospital LOS. <.01; <.05. Error bars denote standard deviation. Insulin glargine + glulisine: 0.4 units/kg for BG mg/dl; 0.5 units/kg for BG mg/dl (1/2 daily dose given as basal insulin). SSI = regular insulin 4 times daily for BG > 140 mg/dl. *P P Umpierrez GE, et al. Diabetes Care. 2007;30: Basal Bolus vs Sliding Scale in the RABBIT 2 Surgery Study Outcomes and Hypoglycemia Achievement of Glucose Goals Percent of Pa ents with BG <140 mg/dl 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Hospital Complications* BG <70 mg/dl BG <40 mg/dl Basal Bolus 8.6% 23.1% 3.8% Sliding Scale 24.3% 4.7% 0% P value < P < % 31% Scheduled Basal Bolus Sliding Scale * Composite of postoperative complications including wound infection, pneumonia, bacteremia, and respiratory and acute renal failure. Umpierrez GE, et al. Diabetes Care Feb;34:
18 Case Study A 48-year-old woman is ready to eat 36 hours after coronary artery bypass graft surgery Between 1 AM and 7 AM, she was receiving an average of 2 units of intravenous regular insulin per hour, with a glucose level of mg/dl She was given a small amount of juice at 7 AM, and her glucose level increased to 195 mg/dl, prompting an increase in the infusion rate to 3 U/h 35 How would you convert her 30 units of premixed insulin twice a day to basal bolus insulin? Total daily dose = 60 units; give half as basal (30 units long-acting basal analog at bedtime, 30 units as mealtime insulin divided at each meal [10 units rapidacting analog three times daily when food served) 36 18
19 How would you estimate basal bolus insulin dosing if prior insulin dose informatin was not available? Weight-based calculation: Patient is 100 kg 0.5 u/kg for TDD = 50 units; give half as basal (25 units long-acting basal analog at bedtime, 25 units as mealtime insulin divided at each meal [8 units rapidacting analog three times daily when food served) 37 Modifications to Therapy Nursing is instructed to hold the rapid-acting insulin if the meal is missed or the glucose level is low Correctional insulin is ordered to be added if the glucose level exceeds the target glucose range 38 19
20 Case Study (Cont.) The patient goes for an X-ray at 11:45 am The lunchtime dose of insulin has already been administered During the procedure, she feels shaky and panicky Point of care blood glucose testing reveals a blood glucose level of 68 mg/dl 39 Hypoglycemia Should be Defined as? 1. < 50 mg/dl 2. < 70 mg/dl 3. < 90 mg/dl 40 20
21 Essential Part of Insulin Therapy: Hypoglycemia Protocol Clear definition of hypoglycemia (BG < 70 mg/dl) Nursing order to treat without delay Stop insulin infusion (if patient is on one; unless T1DM) Oral glucose (if patient is able to take oral) IV dextrose or glucagon (if patient is unable to take oral) Repeat blood glucose (BG) monitoring 15 min after treatment for hypoglycemia and repeat treatment if BG not up to target Directions for when and how to restart insulin Look for the cause of hypoglycemia and determine if other treatment changes are needed Moghissi ES, et al. Endocr Pract. 2009;15(4):1-17. Moghissi ES, et al. Diabetes Care. 2009;32(6): Example Hypoglycemia Protocol If patient CAN safely swallow without aspirating If patient CANNOT safely swallow or patient has NPO status If BG mg/dl: Give 4 oz. juice or regular soda If BG mg/dl: Give 1 dose D50W IV push If BG 49mg/dL: Give 8 oz. juice or regular soda If BG 49mg/dL: Give 1 dose glucagon IM Recheck BG in min. If BG <70 mg/dl, then continuously repeat until BG 70 mg/dl and notify provider. Once BG >70 mg/dl, repeat BG monitoring in 1 hour and check again in 2 hours. Notify provider of insulin adjustments and changes in BG monitoring. If BG level has not remained 70 mg/dl for both BG checks, notify provider for further insulin adjustments and changes in BG level monitoring Roe ED, Raskin P. Hosp Pract. 2012; 40;
22 Case Study, cont d The patient is given 4 oz. of orange juice Repeat blood glucose check shows BG = 100 mg/dl Her insulin regimen is resumed A review of the day s BG levels shows that, except for the x-ray incident, no BG < 90 mg/dl and there were some BG 180 mg/dl 43 How would you adjust her dose? 1. Keep the same dose 2. Increased dose by 10% 3. Decrease dose by 10% 44 22
23 Daily Dose Adjustment Determine yesterday s total insulin dose actually administered Review yesterday s glycemic control Calculate today s scheduled insulin dose Some BG < 90 mg/dl 80% of yesterday s total BG mg/dl 100% of yesterday s total Some BG 180 mg/dl, no BG < 90 mg/dl 110% of yesterday s total McDonnell M, Donahue MACP Hospitalist. 2009; Transition to outpatient status 23
24 Case Study 56-year old obese female status post hysterectomy diagnosed with type 2 diabetes during hospitalization (A1C 8%) 120 kg During hospitalization, she was treated with 30 units basal insulin analog; 10 units rapid acting insulin at each meal FBG = 110 mg/dl, PPG = 125 mg/dl 47 Case Study: With what antihyperglycemic therapy would you discharge this patient? Basal bolus insulin Basal insulin + metformin Premixed insulin Metformin only Diet + exercise only 48 24
25 Transition to Outpatient Status Begin discharge planning early Stabilize blood glucose prior to discharge Obtain A1C for discharge planning if the result is not available from the previous 2 to 3 months A1C can now be used as a means to make the diagnosis of diabetes EL4, expert opinion 49 Discharge Planning: New Hyperglycemia A1C <5.7% 5.7% to 6.4% 6.5% to 7% 7% to 9% >9% General Guidelines Patient does not have diabetes nor pre-diabetes Patient has pre-diabetes (at risk); follow-up advisable; consider diabetes prevention strategies Patient has diabetes; can be treated with lifestyle/consider metformin Patient has diabetes and pharmacotherapy is indicated Most patients would likely benefit from basal-bolus insulin regimen at discharge OGTT = oral glucose tolerance test. Society of Hospital Medicine Glycemic Control Task Force. Workbook for Improvement
26 Discharge Planning: Diagnosed Diabetes A1C <7% 7% to 8% General Guidelines Continue pre-admission diabetes management therapy plan Increase dose of preadmission diabetes medications and/or add a second/third oral agent or basal insulin at bedtime >8% If on 2 diabetes medications, add basal insulin at bedtime >9% to 10% Most patients should be on basal-bolus insulin at discharge Society of Hospital Medicine Glycemic Control Task Force. Workbook for Improvement Case Study With an A1C of 8%, this patient will likely benefit from insulin therapy The choice of insulin regimen may depend on her lifestyle, education, support system, motivation 52 26
27 Transition from Hospital to Home Reinstitute preadmission insulin regimen or oral and non-insulin injectable antidiabetic drugs at discharge for patients with acceptable preadmission glucose control Initiation of insulin administration in those for whom it is indicated at least one day before discharge to allow assessment of the efficacy and safety of this transition Patients and their families/caregivers receive both oral and written instructions regarding their glycemic regimen 53 Transition to Outpatient Status Provide instruction Medication use / Injection technique if using insulin Basics on diet plan Glucose monitoring Hypoglycemia prevention and treatment Refer patient to a certified diabetes educator, if needed Clarify insurance reimbursement to ensure availability of medications at discharge Schedule a follow-up visit with clinician (& emergency number to call if problems) Moghissi ES, et al. Endocr Pract. 2009;15: EL4, consensus
28 Survival Skills to Be Taught Before Discharge How and when to take medication/insulin What to expect from the medication How/when to test BG (SMBG) What are target glucose levels Basics on meal planning How to treat hypoglycemia Sick-day management plan Date/time of follow-up visits Including diabetes education When and who to call on the healthcare team What community resources are available Moghissi E, et al. Endocr Pract. 2009;15: Umpierrez GE et al. J Clin Endocrinol Metab, 2012, 97: Gaps in US Hospital Discharge Planning and Transitional Care Base: Adults with any chronic condition who were hospitalized in past 2 years 2008 Commonwealth Fund International Health Policy Survey of Sicker Adults (data collection: Harris Interactive, Inc.)
29 Use of insulin pumps in the hospital Case Study 41-year old male presents to surgical unit for elective surgery; has been steadfast insulin pump user for 15 years A1C =6.2% Wishes to maintain control of insulin therapy during hospital stay 58 29
30 Do you allow patients to use insulin pumps during hospitalization? 1. Yes 2. No 3. Don t know 59 Insulin Pump Use During Hospitalization With increasing utilization of insulin pump therapy, many institutions allow patients on insulin pumps to continue using these devices in the hospital Others express concern regarding use of a device unfamiliar to staff, particularly in patients who are not able to manage their own pump therapy Which scenario best describes your institution? 60 30
31 Overview of Insulin Pump Therapy Electronic devices that deliver insulin through a SQ catheter basal rate (variable) + bolus delivery for meals Used predominately in Type 1 diabetes, though many Type 2s use CSII Pumpers tend to be very fastidious about their glycemic control They are often reluctant to yield control of their diabetes to the inpatient medical team Generally speaking, hospital personnel are unfamiliar with the workings of insulin pumps Hospitals do not stock infusion sets, batteries, etc. for insulin pumps (4+ brands on market) 61 Insulin Pump Use During Hospitalization Clear policies and procedures should be established at the institutional level to guide continued use of the technology in the acute care setting The availability of hospital personnel with expertise in continuous sc insulin infusion therapy is essential A formal Inpatient Insulin Pump Protocol reduces confusion and treatment variability Umpierrez et al, Endocrine Society Non-ICU Guideline. J Clin Endocrinol Metab Jan;97(1):
32 Insulin Pump Policy : Main Elements Patient qualifications for self-management (normal mental status, able to control device, etc.) Pump in proper functioning order and supplies stocked by patient/family Patient contract / agreement to be signed Order set entry Documentation of doses delivered (pump flow sheet) Ongoing communication between patient and RN Policies re: procedures, surgeries, CTs, MRIs, etc. 63 Insulin Pump Use During Hospitalization Patients who use continuous sc insulin infusion pump therapy in the outpatient setting can be candidates for diabetes -management in the hospital, provided that they have the mental and physical capacity to do so It is important that nursing personnel document basal rates and bolus doses on a regular basis (at least daily) Patient Attestation I confirm that I have been fully trained on the use of my insulin pump prior to this hospitalization and that I am capable and willing to manage it independently during my hospital stay. If at any time I feel that I am unable to manage the pump, I will alert my medical team. Requires patient and witness signature Bailon RM et al Endocrine Practice. 2009;15:25. EL3, retrospective chart review Noschese ML et al Endocrine Practice. 2009;15:415. EL3, review of medical records; EL4, expert opinion 64 32
33 A Validated Inpatient Insulin Pump Protocol Physician Order Set Consult Diabetes Service / Endocrinologist Discontinue all previous insulin orders Check capillary blood glucose frequency Patient to self-administer insulin via pump Patient to document all BG and basal/bolus rates Insulin type order for pump: rapid-acting analogue (lispro, aspart, glulisine) Set target BG range Implement hypoglycemia treatment protocol Noschese et al. Endocrin Pract. 2009;15: A Validated Inpatient Insulin Pump Protocol Basal Insulin Rates Start Time Stop Time Basal Rate Units/hr Start Time Stop Time Basal Rate Units/hr Start Time Stop Time Basal Rate Units/hr 12 am 1 am am 9 am pm 5 pm am 2 am am 10 am pm 6 pm am 3 am am 11 am pm 7 pm am 4 am am pm 8 pm am 5 am pm pm 9 pm 6 am 12 pm 8 pm 5 am am 2 pm 10 pm 6 am 1 pm 9 pm pm 8 am 3 pm 10 pm 7 am 2 pm 3 pm 4 pm pm 12 am 0.7 Patient to self-administer insulin via SQ insulin pump and document all basal rates. Noschese et al. Endocrin Pract. 2009;15:
34 A Validated Inpatient Insulin Pump Protocol Meal Boluses based on: Carbohydrate count Fixed doses Breakfast u/per gram u at Breakfast Lunch u/per gram Supper or u/per gram u at Lunch u at Supper u with Snacks Snacks u/per gram Correction boluses: unit(s) for every mg/dl over mg/dl (target glucose) Noschese et al. Endocrin Pract. 2009;15: A Validated Inpatient Insulin Pump Protocol 50 patient hospitalizations after implementation of an Inpatient Insulin Pump Protocol (IIPP) 3 groups: Mean BG (mg/dl) Group 1 - IIPP+DM consult (34) 173 ±43 Group 2 - IIPP alone (12) 187 ±62 Group 3 - Usual care (4) P=NS 218 ±46 More inpatient days with BG>300 in Group 3 (p<0.02.) No differences in inpatient days with BG<70 1 pump malfunction; 1 infusion site problem; no SAEs 86% of pumpers expressed satisfaction with ability to manage DM in the hospital Noschese et al. Endocrin Pract. 2009;15:
35 Inpatient Insulin Pump Therapy: A Single Hospital Experience 65 patients (125 hospitalizations) Age (mean) 57 ±17 yrs; DM duration 27 ±14 yrs, pump use 6 ±5 yrs; A1C 7.3 ±1.3%; LOS 4.7 ±6.3days Pump therapy continued 66% Endocrine consults in 89% Consent agreements in 83% Pump order sets completed in 89% RN assessment of infusion site in 89% Bedside insulin pump flow sheets in only 55% Mean BG 175 mg/dl (same as off pump) No AEs (one catheter kinking) Nassar et al. J Diab Sci Technol. 2010;4: Summary Optimizing Care of the Inpatient with Hyperglycemia is Challenging! Inpatient situations are unstable No single algorithm is suitable for all patients Many scenarios require increased monitoring and possible adjustments in insulin dose Transitions in care are important opportunities to reassess glycemic control 70 35
HAP PA-HEN Achieving More Together
HAP PA-HEN Achieving More Together Managing Hyperglycemia in the Hospital: Strategies for Safe and Effective Care Pennsylvania Patient Safety Authority Managing Hyperglycemia in the Hospital: Strategies
More informationInpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, :30 a.m. 11:15 a.m.
Inpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 1, 218 1:3 a.m. 11:15 a.m. There are over 7.5 million hospital admissions for patients with diabetes in the US. About
More informationTransition of Care in Hospitalized Patients with Hyperglycemia and Diabetes
Transition of Care in Hospitalized Patients with Hyperglycemia and Diabetes Critically ill patients in the ICU Hospital Non-ICU Settings Home Guillermo E Umpierrez, MD, FACP, FACE Professor of Medicine
More informationSpecial Situations 1
Special Situations 1 Outline Continuous Nutrition Tube feeds TPN Steroids Pumps Perioperative BG Control 2 Patient receiving continuous TF or TPN Continuous nutrition coverage options: Analog q4hr Regular
More information4/10/2015. Foundations to Managing Inpatient Hyperglycemia. Learning Objectives
Foundations to Managing Inpatient Hyperglycemia Module A 1 Learning Objectives Develop strategies to identify patients with hyperglycemia or diabetes in the inpatient setting Establish glycemic goals to
More informationEvidence for Basal Bolus Insulin Versus Slide Scale Insulin
Curr Emerg Hosp Med Rep (2014) 2:26 34 DOI 10.1007/s40138-013-0032-4 DIABETES AND METABOLIC DISEASE (W FORD, SECTION EDITOR) Evidence for Basal Bolus Insulin Versus Slide Scale Insulin Sameer Badlani William
More informationStroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols. Askiel Bruno, MD, MS Protocol PI
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols Askiel Bruno, MD, MS Protocol PI SHINE Synopsis Acute ischemic stroke
More informationInpatient Diabetes Management: The Slippery Slope of Sliding Scale Insulin
Inpatient Diabetes Management: The Slippery Slope of Sliding Scale Insulin David Newman, MD University of North Dakota School of Medicine Sanford Health Big Sky Conference 2017 Dr. David Newman, Personal/Professional
More informationIn-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University
In-Hospital Management of Diabetes Dr Benjamin Schiff Assistant Professor McGill University No conflict of interest to declare CLINICAL SCENARIO 62 y/o male with hx of DM 2, COPD, and HT is admitted with
More informationAPPENDIX American Diabetes Association. Published online at
APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no
More informationInpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, :30 a.m. 11:15 a.m.
Inpatient Management of Hyperglycemia Guillermo Umpierrez, MD, CDE Saturday, February 10, 2018 10:30 a.m. 11:15 a.m. There are over 7.5 million hospital admissions for patients with diabetes in the US.
More informationA Children s Bedtime Story
A Children s Bedtime Story Setting: University Medical Center, Big Town, USA Scenario: 0500, last admission of the night, 10 previous admissions, all tucked in for the night Patient: 75 year old male with
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationΑναγκαιότητα και τρόπος ρύθμισης του διαβήτη στους νοσηλευόμενους ασθενείς
Αναγκαιότητα και τρόπος ρύθμισης του διαβήτη στους νοσηλευόμενους ασθενείς Αναστασία Θανοπούλου Επίκουρη Καθηγήτρια Β Παθολογικής Κλινικής Πανεπιστημίου Αθηνών Διαβητολογικό Κέντρο, Ιπποκράτειο Νοσοκομείο
More informationPharmacy Plan Guidance
Pharmacy Plan Guidance The pharmacy plan is a tool used during the site readiness process to develop and document the site-specific procedures for study drug ordering, labeling and dispensing for the SHINE
More informationBasal Bolus Insulin Therapy Frequently Asked Questions
1. What is Basal Bolus Insulin Therapy (BBIT)? 2. What evidence supports the use of subcutaneous Basal Bolus Insulin Therapy? 3. Does Basal Bolus Insulin Therapy apply to all patients? 4. What s wrong
More informationDiabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical
Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Anne Peters, MD (Chair)
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationPeripartum and Postpartum Management of Diabetes
Peripartum and Postpartum Management of Diabetes General Principles Glucose goal ~ 100 mg/dl (70-110 mg/dl) Labor is EXERCISE with increased metabolic demands. Insulin requirements decrease however the
More informationIn - Hospital Diabetes Care. A review and personal experience
In - Hospital Diabetes Care A review and personal experience Hyperglycemia in the Hospital The Problem Hospitalizations with Diabetes http://www.cdc.gov/diabetes/statistics/dmany/fig1.htm Prevalence of
More informationInsulin Regimens: Hitting Glycemia Targets
Insulin Regimens: Hitting Glycemia Targets Grant Kelley MD March 1 st, 2018 Faculty Disclosure: Financial relationships with commercial interests None Overview Mortality and Morbidity Insulin and Insulin
More informationInpatient Management of Diabetes Mellitus. Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy
Inpatient Management of Diabetes Mellitus Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy 2 Disclosure Jessica Garza does not have any actual or potential conflicts of
More informationManaging Diabetes and Hyperglycemia Safely in the Complex Hospital Setting
Managing Diabetes and Hyperglycemia Safely in the Complex Hospital Setting Greg Maynard MD, MSc Clinical Professor of Medicine and CQO, UC Davis Medical Center Sacramento, CA Greg Maynard Disclosure SHM
More informationGlucose Management in Noncritical Hospitalized Patients
Glucose Management in Noncritical Hospitalized Patients October 17, 2015 Archana R. Sadhu, MD., FACE Director of System Diabetes Program Director of Transplant Endocrinology Assistant Professor, Weill
More informationGlycemic Control Insulin In The Hospital Setting
Glycemic Control Insulin In The Hospital Setting Glycemic Control The Evidence For Insulin s s Benefit The Mechanism of Insulin s s Benefit The Achievement of Insulin s s Benefit A Few Cases Hyperglycemia
More information123 Are You Providing Evidence-Based Diabetes Care? - Martin
Donna Martin, DNP, RN, CDE, CMSRN Lewis University Learner will be able to: Identify current inpatient standards of care for patients with diabetes Describe causes of hyperglycemia / hypoglycemia in the
More informationInsulin Order Sets & In-Hospital Management of Diabetes
Insulin Order Sets & In-Hospital Management of Diabetes 416591 Table of Contents Key elements from Diabetes Canada 2018 Clinical Practice Guidelines Introduction........................................................
More informationGlucose Management in the ICU: The Role of the Pharmacist
Objectives Glucose Management in the ICU: The Role of the Pharmacist James Gilmore PharmD, BCPS Senior Pharmacist- Surgical Intensive Care Unit Brigham and Women s Hospital Boston, MA Evaluate primary
More informationThursday School 2010 Management of Inpatient Diabetes and Hyperglycemia and Quality Improvement Efforts
Thursday School 2010 Management of Inpatient Diabetes and Hyperglycemia and Quality Improvement Efforts Kendall Rogers, MD Using subcutaneous insulin to reliably achieve desired glycemic outcomes in non-critically
More informationGlucose Management in NON-ICU Hospitalized Patients
Glucose Management in NON-ICU Hospitalized Patients October 15, 2016 Archana R. Sadhu, MD., FACE Director of System Diabetes Program Director of Transplant Endocrinology Assistant Professor, Weill Cornell
More informationMeeting the Challenge of Inpatient Glycemic Management in the Non-Critical Care Setting
Meeting the Challenge of Inpatient Glycemic Management in the Non-Critical Care Setting Jane Jeffrie Seley, DNP, MPH, GNP, BC-ADM, CDE, CDTC, FAAN, FAADE Diabetes Nurse Practitioner, Inpatient Diabetes
More informationANNUAL MEETING 2 #FSHP2017
FSHP Disclosure Strategies for Glycemic Management in the Inpatient Setting: Guidelines vs. Reality Melissa Marshall, PharmD, BCPS Jeffrey Ruff, PharmD We do not have (nor does any immediate family member
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationInpatient Glycemic Management:
Disclosure to Participants Conflict of Interest (COI) and Financial Relationship Disclosures: Dr. Seley attended Advisory Board Meeting: Alliance (Boehringer-Ingelheim/Lilly) Bayer Diabetes Care Sanofi
More informationNOT-SO-SWEET! THE STRAIGHT SCOOP ON DIABETES IN THE HOSPITAL SETTING
Sharp HealthCare s 2016 Diabetes Conference November 11, 2016 NOT-SO-SWEET! THE STRAIGHT SCOOP ON DIABETES IN THE HOSPITAL SETTING Tamara Swigert, MSN, RN, CDE Speaker Disclosure Tammy Swigert has no conflicts
More informationType 2 Diabetes Mellitus Insulin Therapy 2012
Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration
More information9/16/2013. No Conflict of Interest to Disclose
Catie Prinzing MSN, APRN, Clinical Nurse Specialist September 27, 2013 No Conflict of Interest to Disclose List key concepts to determining patient insulin doses during transitions in care Identify 5 points
More informationManagement of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting:
T h e E n d o c r i n e S o c i e t y s Clinical Guidelines Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline Authors:
More informationGuide to Starting and Adjusting Insulin for Type 2 Diabetes*
Guide to Starting and Adjusting Insulin for Type 2 Diabetes* www.cadth.ca * Adapted from Guide to Starting and Adjusting Insulin for Type 2 Diabetes, 2008 International Diabetes Center, Minneapolis, MN.
More informationIn-hospital management of diabetes
Dr. Tom Elliott MBBS, FRCPC Medical Director 400-210 W Broadway phone: 604.683.3734 Vancouver, BC fax: 604.628.3821 V5Y 3W2 Canada email: moa@bcdiabetes.ca In-hospital management of diabetes General Management
More informationIn-Hospital Management of Diabetes
In-Hospital Management of Diabetes Clinical order sets guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Table of Contents Key elements from the Canadian Diabetes Association 2013 Clinical Practice
More informationClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationNph insulin conversion to lantus
Nph insulin conversion to lantus Search 26-2-2003 RESPONSE FROM AVENTIS. We appreciate the opportunity to respond to Dr. Grajower s request for information regarding Lantus ( insulin glargine [rdna origin.
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationRecent Advances in the Management of Diabetes
Recent Advances in the Management of Diabetes Raja Hanania, R.Ph,CDM,CDE,LDE,BCPS Clinical Pharmacy Specialist IU Health Bloomington Hospital Bloomington, Indiana Indiana Pharmacists Alliance Annual Convention
More informationThe Diabetes Guidelines Trek: The Next Generation. Inpatient Diabetes Guidelines. Learning Objectives. Current Inpatient Guidelines
The Diabetes Guidelines Trek: The Next Generation J. Christopher Lynch, PharmD, BCACP Southern Illinois University Edwardsville School of Pharmacy Susan Cornell BS, PharmD, CDE, FAPhA, FAADE Midwestern
More information5/15/2018 DISCLOSURE OBJECTIVES. FLORIDA HOSPITAL ORLANDO Not for profit organization Acute care medical center 1,368 licensed beds BACKGROUND
DISCLOSURE PHARMACIST DIRECTED MANAGEMENT OF GLUCOCORTICOID INDUCED HYPERGLYCEMIA AT A LARGE COMMUNITY HOSPITAL Jill Zaccardelli, PharmD PGY1 Pharmacy Resident Florida Hospital Orlando Jill.Zaccardelli@flhosp.org
More informationImproving Glycemic Control in the Critical Care
Improving Glycemic Control in the Critical Care Setting /Hospitalists Outline Review current guidelines Review current glycemic targets DKA Treatment Building a perfect glycemic control protocol Transition
More informationLearning Objectives. Perioperative SWEET Success
Perioperative SWEET Success PERIOPERATIVE SWEET SUCCESS PRESENTED BY: KENDRA MARTIN, RN, BSN, CDE JENNIFER SIMPSON, RN, BC-ADM, MSN, CNS Disclosure to Participants Notice of Requirements For Successful
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationHow to manage type 2 diabetes in medical and surgical patients in the hospital
MEDICAL GRAND ROUNDS CME CREDIT EDUCATIONAL OBJECTIVE: Readers will learn the relationship between glycemic control and clinical outcomes in hospitalized medical and surgical patients who are not in an
More informationHYPERGLYCEMIA MANAGEMENT PROTOCOL A BASAL/BOLUS REGIMEN. Kacy Aderhold, MSN, APRN-CNS, CMSRN
HYPERGLYCEMIA MANAGEMENT PROTOCOL A BASAL/BOLUS REGIMEN Kacy Aderhold, MSN, APRN-CNS, CMSRN Hyperglycemia Management Protocol Mimics the body s normal pancreas function, releasing a slow steady amount
More informationDisclosure. Disclosure. Disclosure. Course Outline. Objectives. A Touch of Sugar : Controlling Hyperglycemia in Acute Care Settings 7/25/2013
47 th Annual Meeting August 2-4, 2013 Orlando, FL A Touch of Sugar : Controlling Hyperglycemia in Acute Care Settings Kevin Forbush, Pharm. D Central Maine Medical Center Lewiston, Maine Disclosure I do
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationLIBERTYHEALTH. Jersey City Medical Center Department of Patient Care Services. Approved by Policy Committee:
LIBERTYHEALTH Jersey City Medical Center Department of Patient Care Services Guidelines: CRITICAL CARE INSULIN PROTOCOL (MICU/SICU, CCU, ED) Developed by: Pharmacy Dept Approved by: Rita Smith, DNP Senior
More informationPHYSICIAN S ORDERS Page 1 of 1 Providence Hospital ICU Insulin Drip Protocol
DTE PROVIDENCE HOSPITL 6801 irport Boulevard, Mobile L 36608, PHYSICIN S ORDERS Page 1 of 1 Providence Hospital ICU Insulin Drip Protocol 1. Discontinue all previous insulin and oral diabetic medications
More informationWelcome Everyone. Monitoring, Sick Days, Inpatient Management - Objectives. Mrs. Jones has new diabetes. She asks you: Page 1
Welcome Everyone Sign-In Enjoy Breakfast Meet someone new Enter Raffle Pick a team name Please silence phones We start at 8:00am Monitoring, Sick Days, Inpatient Management - Objectives Objectives: Strategies
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationObjectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment
Sub Optimal Glycemic Control: Moving to the Appropriate Treatment Judy Thomas, MSN, FNP-BC Holt and Walton, Rheumatology and Endocrinology Objectives Upon completion of this session you will be better
More informationHow to BBIT An Educational Resource for Prescribers AHS Adult Subcutaneous Basal Bolus Insulin Therapy (BBIT)
How to BBIT An Educational Resource for Prescribers AHS Adult Subcutaneous Basal Bolus Insulin Therapy (BBIT) The Basics, New Concepts and Practical Pearls for Basal Bolus Insulin Therapy February 2018
More information9/23/09. What are the key components of preoperative, intraoperative, & postoperative care of diabetes management? Rebecca L. Sturges, M.D.
RMHS Perioperative Summit: Perioperative Diabetes Management Rebecca L. Sturges, M.D. Oct 6, 2009 Mrs. B was referred by her orthopedic surgeon to your preoperative clinic to discuss medical management
More informationDiabetes Head to Toe May 31, 2017
Innovations in Insulin Joanne Reid RN CDE jmreid@gbhs.on.ca Danielle Benedict RPh Outline Setting the stage Insulin as pancreas replacement therapy Commonly used insulins New insulins Case Studies Dosing
More informationDisclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2
Therapy For Diabetes Michigan Association of Osteopathic Family Physicians Mid-Winter Family Medicine Update Shanty Creek Resort, MI January 19-22nd 2017 Michael R. Brennan D.O., M.S., F.A.C.E Director
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
Types of Insulin Rapid-acting insulin: lispro (Humalog), aspart (NovoRapid), glulisine (Apidra) Regular short-acting insulin: Humulin R, Novolin ge Toronto, Hypurin Regular Basal insulin: NPH (Humulin
More informationStroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols Special Situations. Askiel Bruno, MD, MS Protocol PI
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols Special Situations Askiel Bruno, MD, MS Protocol PI Hypoglycemia Protocol General Concepts The hypoglycemia prevention protocol
More informationStroke Hyperglycemia Insulin Network Effort (SHINE) Trial
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols Askiel Bruno, MD, MS Protocol PI Agenda General protocol for control group/ intervention group Discussion of meals Hypoglycemia
More informationSHINE Study PowerChart Order Set CONTROL
SHINE Study PowerChart Order Set CONTROL Orders Patient Care Component Blood Glucose Details Hypoglycemia: For BG
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationDiabetic Ketoacidosis
October 2015 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Case History HPI: 24 yo man with recent 8 lb. weight loss, increased thirst and frequent
More informationImplementing Hospital Policies & Protocols
Implementing Hospital Policies & Protocols Jane Jeffrie Seley DNP MPH GNP BC-ADM CDE CDTC FAADE FAAN Division of Endocrinology, Diabetes & Metabolism NewYork-Presbyterian Hospital Weill Cornell Medicine
More informationIntensive Insulin in the Intensive Care Unit
TABLE OF CONTENTS Introduction to Intensive Insulin in Adult Critical Care Patients - UIMCC Guideline for Insulin Infusion in Adult ICU Patients - P&T Committee Formulary Action Intensive Insulin in the
More informationThe principles of insulin adjustment guidance
The principles of insulin adjustment guidance Tips for insulin titration Blood glucose (BG) monitoring is needed to help identify the efficacy of treatment in diabetes. Monitor blood glucose according
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationThese Aren t Your Average Rookies: A Primer on New and Emerging Insulins. Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP
These Aren t Your Average Rookies: A Primer on New and Emerging Insulins Alissa R. Segal, Pharm.D, CDE, CDTC, FCCP Disclosures Eli Lilly & Company: Advisory board member Boehringer Ingelheim: Advisory
More informationPerioperative Management of the Patient with Endocrine Disease: A Focus on Diabetes & Thyroid Dysfunction
Perioperative Management of the Patient with Endocrine Disease: A Focus on Diabetes & Thyroid Dysfunction Luigi Meneghini, MD, MBA Professor, Internal Medicine (Endocrinology), UT Southwestern Medical
More informationInpatient and perioperative management of hyperglycemia
Inpatient and perioperative management of hyperglycemia Department of Internal Medicine Grand Rounds July 7, 2017 Luigi Meneghini discloses that he has served on advisory boards and as consultant for both
More informationManagement of Inpatient Hyperglycemia: 2011 Endocrine Society Meeting Hyperglycemia in Critically ill patients in ICU Settings.
Management of Inpatient Hyperglycemia: 2011 Endocrine Society Meeting Guillermo E. Umpierrez, MD, Emory University School of Medicine and Jack Leahy, MD, University of Connecticut Hyperglycemia in Critically
More informationLET S TALK INSULIN THE BASICS
LET S TALK INSULIN THE BASICS AUTHOR S DISCLOSURES Contracted for program development for Lifescan Canada Speaker for Lifescan, Lilly, BI, Consultant for Lilly, Janssen, Novo Nordisk, Lifescan Canada OBJECTIVES
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationThe Hospitalized Child with Diabetes/Hyperglycemia: Don t Sugar Coat It
The Hospitalized Child with Diabetes/Hyperglycemia: Don t Sugar Coat It Cassie Brady, MD Assistant Professor of Pediatrics Division of Endocrinology and Diabetes Monroe Carell Junior Children s Hospital
More informationMANAGEMENT OF TYPE 1 DIABETES MELLITUS
MANAGEMENT OF TYPE 1 DIABETES MELLITUS INVESTIGATIONS AND TREATMENT MANSI NAIK VII SEMESTER INVESTIGATIONS FASTING BLOOD SUGAR PLASMA GLUCOSE HEMOGLOBIN A 1c SYMPTOMS OF TYPE 1 DIABETES MELLITUS Polyuria
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) June 2017 Review: June 2020 (earlier if required see recommendations) Bulletin 255: Insulin aspart New Formulation - Fiasp JPC Recommendations:
More informationCHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia
CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia Javier Carrasco, MD, PhD Juan Ramón Jiménez Hospital University of Huelva, Spain Case Study: Medical and Social History A 60 years old female
More informationDiabetes Medical Management Plan
Diabetes Medical Management Plan 1 School District: School: School Year: Grade: Student Name: DOB: Provider Name: Phone #: Fax #: Blood Glucose Monitoring at School Blood Glucose Target Range: - mg/dl
More informationDisclosures. Glycemic Control in the Intensive Care Unit. Objectives. Hyperglycemia. Hyperglycemia. History. No disclosures
Disclosures Glycemic Control in the Intensive Care Unit No disclosures Jorie Frasiolas, Pharm.D., BCPS Clinical Pharmacy Manager, CTICU NewYork-Presbyterian Hospital Columbia University Medical Center
More informationMANAGEMENT OF DIABETES IN PREGNANCY
MANAGEMENT OF DIABETES IN PREGNANCY Ministry of Health Malaysia Malaysian Endocrine & Metabolic Society Perinatal Society of Malaysia Family Medicine Specialists Association of Malaysia Academy of Medicine
More informationReviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationPHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG
DRUG AND TREATMENT *****ALSO ORDER SUB ACUTE DKA IV FLUIDS REGIMEN & SUB ACUTE ELECTROLYTE REPLACEMENT on separate forms ***** Condition/Status For purpose of this DKA Regimen, DKA is considered clear
More information4/16/2018. Flexible Intensive Insulin Therapy (FIIT) in People with Type 2 Diabetes: A Viable Option. Disclosures. Outline. No financial disclosures
Flexible Intensive Insulin Therapy (FIIT) in People with Type Diabetes: A Viable Option Kim Bisanz, MFCS, RDN, LDN, CDE Minnesota Academy of Nutrition & Dietetics Annual Meeting April 19, 18 18 MFMER slide-1
More informationDiabetes: Inpatient Glucose control
Diabetes: Inpatient Glucose control Leanne Current, PharmD, BCPS This activity is funded through the Medicaid section 1115(a) Demonstration Texas Healthcare Transformation and Quality Improvement Program
More informationWhat s so sweet about glycemic control? June 3, 2016
What s so sweet about glycemic control? June 3, 2016 Objectives Provide an overview of why glucose control is important in surgical patient outcomes. Demonstrate an understanding of how anesthetics and
More informationProviding Stability to an Unstable Disease
Basal Insulin Therapy Providing Stability to an Unstable Disease Thomas A. Hughes, M.D. Professor of Medicine - Retired Division of Endocrinology, Metabolism, and Diabetes University of Tennessee Health
More informationThis certificate-level program is non-sponsored.
Program Name: Diabetes Education : A Comprehensive Review Module 5 Intensive Insulin Therapy Planning Committee: Michael Boivin, B. Pharm. Johanne Fortier, BSc.Sc, BPh.LPh, CDE Carlene Oleksyn, B.S.P.
More informationINSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationDRUG ALLERGIES WT: KG
DRUG AND TREATMENT Acute Diabetic Ketoacidosis Condition/Status ***(NOTE)*** For purpose of this DKA Regimen, DKA is considered clear only when the CO2 is GREATER than 18 meq/l and the anion gap is LESS
More informationComparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary
Number 14 Effective Health Care Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions
More information